Larimar registers Phase 3 FORWARD-FA trial of nomlabofusp for Friedreich's ataxiaAug 21Trial updateLarimar Therapeutics, Inc.nomlabofusp
Larimar reports Q2 2026 update on nomlabofusp BLA, Phase 3 timing and cashAug 4Quarterly updateLarimar Therapeutics, Inc.nomlabofusp
Larimar submits first BLA module for nomlabofusp in Friedreich's ataxia, reports open-label dataJun 29Regulatory decisionLarimar Therapeutics, Inc.nomlabofusp
Sign inSign in